Financial Performance Forecast - The company expects a net profit attributable to shareholders for the first half of 2024 to be between 290 million and 330 million yuan, representing an increase of 155.84 million to 195.84 million yuan compared to the same period last year, a year-on-year increase of 116.17% to 145.98% [2]. - The expected net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between 110 million and 140 million yuan, an increase of 7.61% to 36.96% compared to the same period last year [3]. - The total profit for the same period last year was 159.69 million yuan, with a net profit attributable to shareholders of 134.16 million yuan [4]. Revenue Growth - The company's revenue for the first half of 2024 is expected to show steady growth, primarily due to stable sales growth of domestic insulin preparations [5]. Impact of Non-Recurring Items - Non-recurring gains and losses significantly impacted net profit, mainly due to increased fair value changes and investment income from trading financial assets compared to the previous year [5]. Forecast Reliability - The company does not foresee any major uncertainties that could affect the accuracy of this performance forecast [6]. - The forecast data is preliminary and subject to final confirmation in the official 2024 semi-annual report [6].

证券代码：603087 证券简称：甘李药业 公告编号：2024-057 甘李药业股份有限公司 关于使用闲置募集资金进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、本次委托理财概况 2.募集资金的基本情况 经中国证券监督管理委员会《关于核准甘李药业股份有限公司首次公开发行 股票的批复》（证监许可[2020]1075 号）核准，公司获准向社会公众公开发行人 民币普通股（A 股）股票 4,020 万股，发行价为每股人民币 63.32 元，共计募集 资金 254,546.40 万元，扣除发行费用后，实际募集资金净额为 244,113.45 万 元。上述募集资金已于 2020 年 6 月 22 日到位，已经安永华明会计师事务所（特 殊普通合伙）验证，并由其出具安永华明（2020）验字第 61234813_A01 号《验 资报告》。公司已对募集资金进行了专户存储管理，募集资金到账后，已全部存 放于募集资金专项账户内，并与保荐机构中信证券股份有限公司、存放募集资金 的兴业银行股份有限公司北京经济技 ...

证券代码：603087 证券简称：甘李药业 公告编号：2024-056 甘李药业股份有限公司 关于使用闲置募集资金进行现金管理到期赎回的公 告 本次赎回情况如下： 单位：万元 | 受托方 | 产品名称 | 产品类型 | 认购金 | 理财币 | 起息日 | 到期日 | 赎回金 | 实际年 化收益 | 实际收 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 额 | 种 | | | 额 | | 益 | | | | | | | | | | 率 | | | 中国银行 | 挂钩型结构 | | | | | | | | | | 股份有限 | | 银行理财 | | | 2024/02/ | 2024/07/ | | | | | | 性存款（机 | | 23,600 | 人民币 | | | 23,600 | 2.83% | 225.07 | | 公司北京 | 构客户） | 产品 | | | 29 | 01 | | | | | 通州分行 | | | | | | | | | | 二、截至本公告日，公司最近十二个月使用募集资金进行现金管理的 ...

Summary of Conference Call Notes Industry Overview - The industry is experiencing significant growth in the third generation of pre-control and pre-export products, indicating a positive trend in demand [1] - In 2024, the total demand from domestic enterprises in the context of centralized procurement is projected to reach 45%, which represents a 14 percentage point increase compared to previous centralized procurement periods [1] - There is an accelerating trend of domestic substitution within the industry, highlighting a shift towards local products [1]

国泰君安版权所有发送给上海东方财富金融数据服务有限公司.东财接收研报邮箱.ybjieshou@eastmoney.com p1 股 票 研 [Table_Industry] 医药/必需消费 究 甘 李药业(603087) [评Tab级le_I：nve st] 增持 GZR18 减重数据亮眼，研发管线加速推进 上 次评级: 增持 [目Tab标le_T价arg格et] ： 60.03 ——甘李药业跟踪点评 上 次预测: 59.78 [当Ta前bl价e_格Cu：rP rice] 50.94 公 [table_A ut丁ho丹rs] ( 分析师) 甘坛焕(分析师) 姜铸轩(研究助理) 司 0755-23976735 021-38675855 021-38674878 [ Table_Date] 2024.06.23 dingdan@gtjas.com gantanhuan028803@gtjas.com jiangzhuxuan029022@gtjas.com 更 登 记编号 S0880514030001 S0880523080007 S0880123100004 新 本报告导读： 报 [交Ta易ble数_M据ar ...

Summary of Conference Call Notes Industry Overview - The industry is experiencing significant growth in the third generation of pre-control and pre-export products, indicating a strong upward trend in demand [1] - In 2024, the total demand from domestic enterprises in the context of centralized procurement is projected to reach 45%, which represents a 14 percentage point increase compared to previous centralized procurement periods [1] - There is an accelerating trend of domestic substitution within the industry, highlighting a shift towards local products [1]

Investment Rating - The report gives a "Buy" rating for the company with a target price of 61.12 CNY based on a 32x PE for 2025 [2][4]. Core Views - The company is expected to benefit from the release of the impact of centralized procurement, with both volume and price increasing, leading to a new growth phase. In 2023, the company achieved revenue of 2.61 billion CNY (+52%) and a net profit of 340 million CNY, marking a return to profitability [1][15]. - The company is deepening its international expansion, with significant growth in overseas sales, which reached 327 million CNY (+132%) in 2023. The company is in the process of applying for market entry in the US and Europe for its insulin products [1][2]. - The company maintains a strong focus on innovation, with over 15% of revenue invested in R&D over the past three years, leading to a rich pipeline of new insulin products [1][2]. Summary by Sections Section 1: Impact of Centralized Procurement - The company has seen a long-term excellent performance, with revenue growing from 690 million CNY in 2013 to 3.61 billion CNY in 2021, achieving a CAGR of 23%. The first round of national procurement had a significant impact in 2022, but the company returned to profitability in 2023 with a net profit of 340 million CNY [15][22]. - The new procurement cycle is expected to last three years, with a total procurement volume of 41.77 million units, an increase of 151% compared to the previous round, and an average winning price increase of 31% [26][28]. Section 2: International Expansion - The company has been pursuing internationalization since 2005, with rapid growth in international sales. The collaboration with Sandoz AG is expected to enhance its market presence in Europe and the US [1][2]. - The company’s insulin products are in the application phase for the US FDA and European EMA, indicating a strong potential for market entry and growth in these regions [1][2]. Section 3: Innovation Pipeline - The company has a robust innovation strategy, focusing on diabetes treatment with a significant investment in R&D. The pipeline includes advanced insulin products that are currently undergoing clinical trials [1][2]. - The company’s R&D investment has consistently been above the industry average, supporting the development of new therapies and enhancing its competitive position in the market [1][2].

证券代码：603087 证券简称：甘李药业 公告编号：2024-055 重要内容提示： 增持计划的基本情况：甘李药业股份有限公司（以下简称"公司"）高 级管理人员孙程先生计划自 2024 年 5 月 16 日起 6 个月内，以自有资金通过集 中竞价交易方式增持公司股份，合计增持金额为人民币 30 万元（含）-50 万元 （含）。 本次增持计划实施情况：截至公告披露日，孙程先生共计增持公司股份 10,200 股，占公司总股本的 0.0017%，增持金额 490,107.00 元。本次增持计划实 施完毕。 2024 年 6 月 11 日，公司收到副总经理孙程先生《关于完成股份增持计划的 告知函》，现将有关情况公告如下： 一、增持主体的基本情况 1. 增持主体：公司高级管理人员孙程先生 2. 增持主体本次增持计划实施前持有公司股份情况 甘李药业股份有限公司 关于高级管理人员增持公司股份计划实施完成 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 （其中 400,000 股为 2024 年 5 月 24 日获授的限制性股票）， ...

证券代码：603087 证券简称：甘李药业 公告编号：2024-054 甘李药业股份有限公司 2023 年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利 0.2 元 相关日期 | | | 差异化分红送转： 否 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司 2024 年 5 月 16 日的 2023 年年度股东大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本 601,201,750 股为基数，每股派发 现金红利 0.2 元（含税），共计派发现金红利 120,240,350 元。 1. 发放年度：2023 年年度 2. 分派对象： 三、 相关日期 | | | | | 日 | | --- | --- | --- | --- | --- | | 股份类别 Ａ股 | 股 ...

股 票 研 究 [Table_industryInfo] 医药/必需消费 [ Table_Main[ 甘TIna 李fbole] 药 _T 业itle (] 6 03087) [评Tab级le_：Inv est] 增持 上次评级： 增持 欧盟 GMP 检查通过，研发管线加速推进 目标价格： 60.03 上次预测： 60.03 公 ——甘李药业跟踪点评 当前价格： 48.49 司 丁丹(分析师) 甘坛焕(分析师) 姜铸轩(研究助理) 2024.05.31 更 0755-23976735 021-38675855 021-38674878 [交Ta易bl数e_据M arket] 新 dingdan@gtjas.com gantanhuan028803@gtjas.com jiangzhuxuan029022@gtjas.com 证书编号 S0880514030001 S0880523080007 S0880123100004 52周内股价区间（元） 33.10-59.60 报 总市值（百万元） 29,152 告 本报告导读： 总股本/流通A股（百万股） 601/532 流通B股/H股（百万股） 0/0 产品出海取 ...